Levetiracetam Almus (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which regulates neurotransmitter release. By modulating this protein, the drug reduces excessive neuronal firing and stabilises synaptic activity, helping to prevent seizure generation.

The dosage of Levetiracetam Almus is individualized by the prescribing clinician based on the patient’s age, renal function, seizure type, and response to therapy. Only a qualified healthcare professional should determine the appropriate regimen.

Safety data for levetiracetam in pregnancy and lactation are limited. Clinicians should weigh potential benefits against unknown risks and discuss options with the patient. Breastfeeding decisions should also consider the drug’s presence in milk and infant exposure.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levetiracetam offers a distinct mechanism by targeting SV2A, which differs from sodium‑channel blockers like carbamazepine or GABA‑enhancers such as valproate. It generally has fewer drug‑enzyme interactions, but clinicians consider individual seizure patterns, tolerability and comorbidities when selecting therapy.

Store Levetiracetam Almus tablets at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Levetiracetam Almus is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed.

Serious adverse events include severe allergic reactions (e.g., rash, swelling, breathing difficulty), mood disturbances such as depression or suicidal thoughts, and rare hematologic or hepatic abnormalities. Patients should seek immediate medical attention if any of these occur.

Levetiracetam is contraindicated in individuals with known hypersensitivity to levetiracetam or any of its excipients. Caution is advised for patients with severe renal impairment, uncontrolled psychiatric conditions, or those taking interacting medications listed under major interactions.